Financial Performance - Q2 2025 sales increased by 26% to $386.9 million compared to $307.2 million in Q1 2025[34] - Adjusted EBITDA improved significantly from $(26.8) million in Q1 2025 to $21.6 million in Q2 2025[34] - Adjusted EBITDA margin increased from (9)% in Q1 2025 to 6% in Q2 2025[34] - Adjusted diluted EPS improved from $(0.20) in Q1 2025 to $(0.08) in Q2 2025[34] - The company generated positive operating cash flow of $15.6 million in Q2 2025 compared to $19.4 million in Q1 2025[44] Market and Operations - The company withdrew guidance due to uncertainty and limited visibility in the market[12, 50] - Silicon metal revenue increased 24% to $130 million in Q2 2025[38] - Silicon-based alloys revenue increased 23% to $112 million in Q2 2025[41] - Manganese-based alloys revenue increased 43% to $106 million in Q2 2025[43] Strategic Outlook - The company expects EU safeguards and the U S silicon metal trade cases to improve 2026 results[12]

Financial Performance - Net sales for Q2 2025 were $330.3 million [8], a decrease of 4.4% compared to $345.5 million in Q2 2024 [44] - Adjusted EBITDA for Q2 2025 was $33.7 million [8], an increase of 22.1% compared to $27.6 million in Q2 2024 [44] - Adjusted EBITDA margin for Q2 2025 was 10.2% [8], an increase of 220 bps compared to 8.0% in Q2 2024 [44] - Adjusted EPS for Q2 2025 was $0.88 [8], an increase of 44.3% compared to $0.61 in Q2 2024 [44] - Free cash flow was $9.0 million in Q2 2025 [8], representing 53.9% of net income [8] Segment Performance - Infrastructure Solutions net sales for Q2 2025 were $204.6 million [47], a decrease of 7.6% compared to $221.4 million in Q2 2024 [47] - Infrastructure Solutions segment operating adjusted EBITDA margin for Q2 2025 was 15.7% [47], an increase of 340 bps compared to 12.3% in Q2 2024 [47] - Materials Solutions net sales for Q2 2025 were $125.7 million [50], an increase of 1.3% compared to $124.1 million in Q2 2024 [50] - Materials Solutions segment operating adjusted EBITDA margin for Q2 2025 was 11.3% [50], an increase of 310 bps compared to 8.2% in Q2 2024 [50] Backlog and Orders - The backlog level is $380.8 million [8]

Pipeline Progress - Pilavapadin 10 mg consistently delivered clinically meaningful pain reduction in Phase 2 trials[8] - Lexicon plans to present full Phase 2 results for Pilavapadin in September 2025 and partnership discussions are ongoing[5] - IND-enabling studies of LX9851 are on track to be completed in 2025[5] - Accelerated site initiations are underway for the Phase 3 SONATA-HCM study of sotagliflozin in HCM[5] Sotagliflozin in HCM - Approximately 1.1 million people in the U S have either obstructive or non-obstructive HCM[15] - 30% of HCM patients are diagnosed with oHCM and 70% are diagnosed with nHCM[16] - The SONATA-HCM Phase 3 study is evaluating sotagliflozin 400 mg versus placebo in 500 patients with oHCM and nHCM[22] - Enrollment in the SONATA-HCM Phase 3 study is accelerating, with all sites expected to be active by the end of Q3 2025[23] Financial Performance - Lexicon reported $28.9 million in total revenues for Q2 2025, including $1.3 million in net product revenues and $27.5 million in licensing revenue[30] - The $27.5 million in licensing revenue includes an upfront payment for the exclusive licensing agreement of LX9851 with Novo Nordisk[31] - Total operating expenses for 2025 are now expected to be between $105 million and $115 million[33]

Company Strategy & Performance - Chimera Investment Corp is a hybrid mortgage REIT focused on diversified investment solutions across the mortgage credit product spectrum[10, 13] - The company reported earnings available for distribution of $039 per share[19] - Book value per share was $2091, a 12% decrease from the previous quarter[22] - Economic return for the quarter was 05%[19, 22] HomeXpress Acquisition - Chimera entered into a definitive agreement to acquire HomeXpress Mortgage Corp, expected to close in Q4 2025[11, 21, 22] - The acquisition consideration includes cash equal to HomeXpress's book value plus a $120 million premium and 2,077,151 shares of CIM common stock[22] - HomeXpress has originated over $107 billion in loans since 2016[25, 27] - HomeXpress generated $47 million in pre-tax earnings in 2024[27] Portfolio Composition & Activity - The company purchased $19 billion in notional Agency pass-throughs, with an additional $402 million settling in Q3[22] - Recourse leverage increased to 18x from 12x in Q1 due to growth in Agency RMBS allocation[22] - Loans under third-party asset management grew 43% year-over-year to $254 billion[57, 58]

Financial Performance & Strategy - The company generated positive free cash flow of $13 million in 2Q25 and $19 million in 1H25, maintaining a strong balance sheet with a net leverage ratio of 1.5x[10] - Backlog increased to approximately $980 million, supported by strong order entry growth of approximately 10% year-over-year[10] - The company is executing on an initial $100 million share repurchase authorization, with approximately $30 million repurchased in 2Q25, representing approximately 637,000 shares[10] - The company reaffirms its 2025 outlook and is trending toward the higher end of the range[10] - The company is targeting mid-single digit annual revenue growth rate by 2027, double-digit Adjusted EBITDA growth & ~15% margins by 2027, and plan to deliver $800 million in cumulative FCF from '25-27 and 60%+ FCF conversion in 2027[16] Segment Performance - Banking revenue increased sequentially, with total banking revenue reported as $679 million[45] - Banking gross profit increased sequentially, with total banking gross profit reported as $187 million, resulting in a gross margin of 27.5%[45,47] - Retail revenue increased sequentially, with total retail revenue reported as $236 million[51] - Retail gross profit increased sequentially, with total retail gross profit reported as $56 million, resulting in a gross margin of 23.7%[51,53] 2025 Guidance - The company reaffirms its 2025 guidance, expecting flat to low single-digit revenue growth, adjusted EBITDA between $470 million and $490 million, and free cash flow between $190 million and $210 million[56]

Financial Performance - Net sales reached $1056 million, a decrease of 0.9% year-over-year[16] - Organic net sales experienced a slight decrease of 0.1% year-over-year[16] - Adjusted gross profit was $403 million, down 6.9% year-over-year[16] - Adjusted gross margin was 38.1%, a decrease of 250 basis points[16] - Adjusted operating income was $1352 million, down 2.9% year-over-year[16] - Adjusted EPS increased by 7.5% to $057[16] Segment Performance - Consumer Self-Care Americas (CSCA) net sales decreased by 1.9% year-over-year to $622 million[43] - Consumer Self-Care International (CSCI) net sales increased by 0.7% year-over-year to $4343 million[43] - Perrigo OTC brands grew by 3.6%, while Perrigo OTC store brands decreased by 3.2%[19] Strategic Initiatives - Infant formula net sales increased by 9% year-over-year[14] - Store brand and contract infant formula net sales increased by 32% year-over-year[26] - Project Energize is expected to deliver $159 million in annual run rate gross savings[30] - Supply Chain Reinvention is expected to generate total benefits between $150-$200 million by the end of 2025[30] - The sale of the Dermacosmetics business is expected to close in Q1 2026, with proceeds prioritized for accelerating net leverage goals[30, 52]

Financial Performance - The company's net investment income (NII) per share was $0.47, resulting in an annualized NII yield on book value of 10.7%[15] - Net income per share was $0.37, equating to an annualized return on book value of 8.3%[15] - The net asset value (NAV) per share decreased slightly to $17.56 as of June 30, 2025, compared to $17.64 as of March 31, 2025[15] - The Board of Directors declared a dividend of $0.42 per share for the third quarter of 2025, along with an additional dividend of $0.03 per share[15] Portfolio Composition and Activity - The total investment portfolio at fair value reached $2,501.8 million, primarily consisting of senior secured, floating-rate loans[15] - Gross investment fundings amounted to $529.6 million, while net investment fundings were $27.3 million[15] - The investment portfolio is diversified across 185 portfolio companies operating in 29 different industries[15] - The weighted average yield at amortized cost on the investment portfolio was 11.4%[15] - Investments on non-accrual represented 1.7% of the total investment portfolio at amortized cost and 0.6% at fair value[15] Liquidity and Funding - The company reported strong liquidity totaling $796 million, including $592 million of undrawn capacity on a revolving credit facility[15] - Unsecured debt represents 61% of the total debt outstanding at quarter-end[15]

Forward Looking Statements This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this communication that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: the timing and results of our clinical studies and data readouts; current or future products or product candidates and their potential benefits; our clinical development plans; comm ...

Q2 2025 Highlights & Supplemental Information August 6, 2025 Certain statements in this presentation are forward-looking statements, including our Q3 2025 and full-year 2025 guidance and our expectations for Realize, our new performance advertising platform. Forward-looking statements generally relate to future events including future financial or operating performance of Taboola.com Ltd. (the "Company"). In some cases, you can identify forward-looking statements by terminology such as "may", "should", "exp ...

Thomson Reuters 2025 Second-Quarter Results August 6, 2025 euters TRI NasdaqListed Agenda | ● | Welcome / Introduction | Gary Bisbee | | --- | --- | --- | | ● | Second-Quarter 2025 Highlights | Steve Hasker | | | Product & Innovation Update | David Wong | | ● | Financial Review | Mike Eastwood | | | Second-Quarter 2025 Results | | | | 2025 Full-Year Outlook Update | | Q & A ● 2 Special Note Special Note Reqarding Forward-Looking Statements, Material Assumptions and Material Risks This presentation consists ...